Braxia Scientific Q2 2023 Financial Results: Health Clinic Ketamine Treatments Increases 34.5% YoY
Braxia Scientific Q2 2023 Financial Results: Health Clinic Ketamine Treatments Increases 34.5% YoY
Braxia Scientific Corp., (CSE:BRAX) (OTC:BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, announced the filing of its financial statements and management discussion and analysis for the second quarter ended September 30, 2022.
"We are executing our vision to increase access to novel treatments such as Ketamine and Psilocybin to address mental health disorders such as depression, anxiety, bipolar disorder, and post-traumatic stress disorder (PTSD)," said Dr. Roger McIntyre, CEO of Braxia Scientific.
Q2 2023 Financial Summary
Q2 2023 in-clinic treatments increased 34.5% year-over-year. In the first 6 months of...
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧